RegulatoryOfficial
EU and Japan's AMED to continue medical countermeasures cooperation on cross-border health threats
🇪🇺 European Commission (DG SANTE) · Mon 16 Nov 2026
DG HERA and Japan's AMED have confirmed by exchange of letters that they will keep working together under their 2023 arrangement on preparedness for serious cross-border infectious disease threats.
The European Commission, through its Health Emergency Preparedness and Response Authority (DG HERA), and the Japan Agency for Medical Research and Development (AMED) will continue their cooperation on medical countermeasures. The stated aim is to strengthen prevention, preparedness and response to serious cross-border health threats.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Official source: European Commission (DG SANTE) ↗
Article written by VigiEye from the official source (European Commission (DG SANTE)). AI-assisted; check the source before acting.
More Regulatory
All →
FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027
Belite Bio, Inc (BLTE) · Fri 20 Nov 2026
FDA publishes new and revised draft product-specific guidances on bioequivalence for generics
🇺🇸 FDA · Fri 20 Nov 2026
Dutch inspectorate posts Biotronik field safety notice on ICD and CRT-D lithium plating
🇳🇱 IGJ · Thu 19 Nov 2026
Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026